Keros Therapeutics Statistics Share Statistics Keros Therapeutics has 40.62M
shares outstanding. The number of shares has increased by 8.24%
in one year.
Shares Outstanding 40.62M Shares Change (YoY) 8.24% Shares Change (QoQ) 0.13% Owned by Institutions (%) 85.15% Shares Floating 33.72M Failed to Deliver (FTD) Shares 4,961 FTD / Avg. Volume 0.88%
Short Selling Information The latest short interest is 5.05M, so 12.43% of the outstanding
shares have been sold short.
Short Interest 5.05M Short % of Shares Out 12.43% Short % of Float 19.48% Short Ratio (days to cover) 11.54
Valuation Ratios The PE ratio is -3.16 and the forward
PE ratio is -3.24.
Keros Therapeutics's PEG ratio is
0.82.
PE Ratio -3.16 Forward PE -3.24 PS Ratio 166.94 Forward PS 23.6 PB Ratio 1.04 P/FCF Ratio -3.64 PEG Ratio 0.82
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Keros Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 21.45,
with a Debt / Equity ratio of 0.03.
Current Ratio 21.45 Quick Ratio 21.45 Debt / Equity 0.03 Debt / EBITDA -0.1 Debt / FCF -0.12 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $21.78K Profits Per Employee $-1.15M Employee Count 163 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax 300K Effective Tax Rate -0.16%
Stock Price Statistics The stock price has increased by -70.23% in the
last 52 weeks. The beta is 1.33, so Keros Therapeutics's
price volatility has been higher than the market average.
Beta 1.33 52-Week Price Change -70.23% 50-Day Moving Average 14.06 200-Day Moving Average 22.06 Relative Strength Index (RSI) 43.49 Average Volume (20 Days) 562,535
Income Statement In the last 12 months, Keros Therapeutics had revenue of 3.55M
and earned -187.35M
in profits. Earnings per share was -5.
Revenue 3.55M Gross Profit 3.55M Operating Income -210.83M Net Income -187.35M EBITDA -185.82M EBIT -187.05M Earnings Per Share (EPS) -5
Full Income Statement Balance Sheet The company has 559.93M in cash and 18.86M in
debt, giving a net cash position of 541.07M.
Cash & Cash Equivalents 559.93M Total Debt 18.86M Net Cash 541.07M Retained Earnings -568.78M Total Assets 757.16M Working Capital 698.1M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -160.87M
and capital expenditures -1.93M, giving a free cash flow of -162.8M.
Operating Cash Flow -160.87M Capital Expenditures -1.93M Free Cash Flow -162.8M FCF Per Share -4.35
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -5938.96% and -5277.55%.
Gross Margin 100% Operating Margin -5938.96% Pretax Margin -5269.1% Profit Margin -5277.55% EBITDA Margin -5234.48% EBIT Margin -5938.96% FCF Margin -4585.92%
